MariTime HF
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Obesity and Heart Failure
- Stadium
- inclusie
- Middel
- Meridebart Cafraglutide
- Populatie
- Hartfalen
- Fase
- III
- First Patient In
- 14 oktober 2025
- Last Patient In
- 28 oktober 2026
- Last Patient Last Visit
- 29 september 2030
Inclusieperiode, nog 333 dagen over
National Lead
dr. P van der Meer
Cardioloog
Studiedirecteur
dr. C.A. da Fonseca
Cardioloog
Contact Kantoor
